# COMMETS- Combination MCI Metabolic Syndrome

> **NCT06072963** · PHASE2 · RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 80 (estimated)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment
- Metabolic Syndrome

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Intranasal insulin
- **OTHER:** Semaglutide placebo
- **OTHER:** Intranasal insulin placebo

## Key facts

- **NCT ID:** NCT06072963
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-30
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06072963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06072963, "COMMETS- Combination MCI Metabolic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06072963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*